Safety and Efficacy of Extended-Release Niacin for the Treatment of Dyslipidaemia in Patients with HIV Infection: Aids Clinical Trials Group Study A5148

Meixner, Linda; Hoffman, Julie; Zwickl, Beth; Goldman, Mitch; Whitely, Kim; Conrad, Ann; J. Fichtenbaum, Carl; Hyc, Fran; Spitz, Teresa; Demarco Shaw, Debra; Norris, Jane; Stoudt, Sylvia; G. Castro, José; F Colon, L; Cavert, Winston; A. Fox, Kathy; P. Dubé, Michael; Wu, Julia; A. Aberg, Judith; A. Deeg, Mark; Alston‐Smith, Beverly; E. McGovern, Mark; Lee, Daniel; Shriver, S.; I. Martínez, Ana; Greenwald, Martha; H. Stein, James

doi:10.1177/135965350601100802

Public

Safety and Efficacy of Extended-Release Niacin for the Treatment of Dyslipidaemia in Patients with HIV Infection: Aids Clinical Trials Group Study A5148

Published in Antiviral Therapy • Nov 1, 2006

Authors:

Linda Meixner

Julie Hoffman

Beth Zwickl

Abstract

BACKGROUND: Dyslipidaemia is very common in patients with HIV infection, but current therapies are often suboptimal. Since niacin may cause insulin resistance and hepatotoxicity, it has generally been avoided in this setting. METHODS: Non-diabetic male subjects (n=33) who had well-controlled HIV inf...

Subject

Internal medicine

Insulin resistance

Niacin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!